Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Multi-Center Study of Eculizumab in Patients With Generalized Myasthenia Gravis (gMG) Who Have Moderate to Severe Muscle Weakness Despite Treatment With Immunosuppressants
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- Sponsors Alexion AstraZeneca Rare Disease
- 01 May 2020 Results (n=7) of cluster analysis assessing effects of complement inhibitor therapy on lymphocyte subsets and peripheral cytokines in immunosuppressed generalized myasthenia gravis patients were presented at the 72nd Annual Meeting of the American Academy of Neurology
- 01 Aug 2017 Results of correlation between QMG and MG-ADL published in the Muscle and Nerve
- 18 Oct 2016 Status changed from completed to discontinued.